BioSpace News Archive

MJH Life Sciences™ has officially launched Medical World News®, a first-of-its-kind 24-hour news program. Content for the program pulls from across all brands within the MJH portfolio, offering insights on the latest news in health care.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Jack W. Schuler has retired from the Company’s Board of Directors effective June 10, 2020. Mr. Schuler has served on the board since February 2006. “As a member of our Board for the last 14 years, Jack leaves a legacy of market leadership, a

As Americans become accustomed to wearing face masks in public to slow the spread of COVID-19, many are experiencing some unpleasant challenges that can arise from covering their breathing, including anxiety, headaches, confusion, and fatigue. PN Medical,

Armis®, the leading enterprise IoT security company, announced today that the Armis Agentless Device Security Platform has been named a Leader by Forrester Research in The Forrester New Wave™: Connected Medical Device Security Q2, 2020.

Sexton Biotechnologies has announced a new collaboration with BioSpherix Medical . As a tool and technologies partners of the Cell and Gene industry, Sexton and BioSpherix both recognize the need for cost-effective and flexible automation solutions during cell and gene therapy process development. While some upstream bioprocesses hav

NAMSA, the world’s only 100% medical device-focused Contract Research Organization (CRO) offering end-to-end development solutions, is pleased to announce the launch of its new website.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) (Germany: TQB2) subsidiary U-Protein Express BV (“UPE”) today announced the availability of its new recombinant SARS-CoV-2 proteins, and other proteins associated with COVID-19,

Initiation follows positive results from cohort 7 of phase 1b COSMIC-021 trial – – CONTACT-01 is the first of three phase 3 pivotal trials that are part of a previously announced clinical collaboration with Roche –

Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved NYVEPRIA™ (pegfilgrastim-apgf), a biosimilar to Neulasta ® (pegfilgrastim). 1 NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence

Phase 3 study of 30,000 subjects expected to begin in July 2020 at 100 μg dose level Manufacturing scale up with Lonza on track to supply 500 million to 1 billion 100 μg doses per year Completed enrollment of younger adults in the Phase 2 study of mRNA-1273 (n=300); also completed enrollment of the sentinel group of older adults (n=50)